Challenges associated with treatment of left internal mammary artery graft thrombosis

Iosif Xenogiannis1, Evangelia Vemmou1, Ilias Nikolakopoulos1

  • 1Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.

Insights

Late acute occlusion of a left internal mammary artery (LIMA) graft caused a heart attack 19 years after bypass surgery. Stent implantation successfully restored blood flow, resolving the life-threatening complication.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Interventional Cardiology

Background:

  • Acute occlusion of the left internal mammary artery (LIMA) graft is a rare but serious complication after coronary artery bypass grafting (CABG).
  • Late graft occlusion can lead to acute myocardial infarction (MI), posing a significant threat to patient survival.

Related Concept Videos

Internal Energy02:00

Internal Energy

The total of all possible kinds of energy present in a substance is called the internal energy (U), sometimes symbolized as E. Suppose a system with initial internal energy, Uinitial, undergoes a change in energy (transfer of work or heat), and the final internal energy of the system is Ufinal. Change in internal energy equals the difference between Ufinal and Uinitial.
36.6K
Internal Energy01:29

Internal Energy

The internal energy of a thermodynamic system is the sum of the kinetic and potential energies of all the molecules or entities in the system. The kinetic energy of an individual molecule includes contributions due to its rotation and vibration, as well as its translational energy. The potential energy is associated only with the interactions between one molecule and the other molecules of the system. Neither the system's location nor its motion is of any consequence as far as the internal...
6.9K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
586
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.4K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
433
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
451